GAT100
Covalent probe of the CB1 allosteric site: a negative modulator more potent than Org27569, without inverse agonism.
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
C₂₅H₂₈N₄OS
CAS 1663564-42-8
- Family
- ECS pharmacological toolAllosteric modulator
- Molar mass
- 432.60 g/mol
Updated on
In plain terms
GAT100 does not activate the CB1 receptor and does not sit on the site targeted by cannabinoids: it binds elsewhere on the receptor and dampens its response. It attaches irreversibly, which makes it a laboratory tool for mapping this second site. It has been studied only in cells; no study in humans was found.
Receptors and activity
Target network
- Blocks or inhibits
The lower the cited value, the closer the target sits to GAT100: one ring per factor of 100. A target with no measured value stays on the edge.
Where these targets live
Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of GAT100.
CB1CB1 found in 7 regions of the body
- Basal gangliadenseMost dense in basal ganglia outflow nuclei1
- CerebellumdenseVery dense in the cerebellum1
- HippocampusdenseVery high concentrations in the hippocampus2
- AmygdaladenseHigh concentrations in the amygdala2
- CortexpresentPresent throughout the neocortex2
- Adipose tissuepresentExpressed in adipose tissue3
- GutpresentColonic epithelium, smooth muscle and plexus4
Map sources
- Herkenham M et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A, 1990 (new tab)
- Glass M et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997 (new tab)
- Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
- Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)
Cited values
- CB1 (allosteric site)Negative allosteric modulatorno measured value cited
Covalent negative allosteric modulator of the signalling induced by CP55,940, 2-AG and anandamide (β-arrestin 1, PLCβ3, ERK1/2, cAMP, internalisation); potentiates [3H]CP55,940 binding; without inverse agonism; no numerical value in the abstracts (Laprairie et al. 2016; Kulkarni et al. 2016)
Pharmacology
GAT100 is a covalent probe of the allosteric site of the CB1 receptor. Kulkarni and colleagues described in 2016 the first ligands designed to bind irreversibly to this site, by introducing an electrophilic or photoactivatable group into Org27569 and PSNCBAM-1, two reference negative allosteric modulators; compound 20, GAT100, emerged as the most potent in functional assays, without inverse agonism, and it also potentiated CP55,940 binding. Laprairie and colleagues profiled it across five downstream pathways (β-arrestin 1 recruitment, phospholipase C β3 and ERK1/2 phosphorylation, cAMP accumulation, CB1 internalisation): it dampens the response to CP55,940, 2-arachidonoylglycerol and anandamide, in three cell systems of which two express CB1 endogenously, with greater potency and efficacy than Org27569 and PSNCBAM-1. Modelling identifies cysteine C7.38(382) as a key element of its binding. This work concerns cells and membranes; no study in animals or humans was found.
Key sources.
- Kulkarni PM et al. Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s). J Med Chem, 2016 (new tab)PMID 26529344
- Laprairie RB et al. Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe. ACS Chem Neurosci, 2016 (new tab)PMID 27046127
- PubChem, GAT100, CID 121453184 (identifiers and properties) (new tab)
History
- Source
- An entirely synthetic compound, with no natural occurrence found. It is described as a covalent pharmacological probe intended to map the allosteric site of the CB1 receptor (Kulkarni et al. 2016); no clinical use was found.
Origin
Research tool
No biological pathway: GAT100 is a synthetic compound, an indole-2-carboxamide derivative of Org27569 bearing an isothiocyanate group, unrelated to the plant cannabinoid pathway.
Legal framework
- European Union
The substance is not listed in the Annex to Council Framework Decision 2004/757/JHA (consolidated version of 12 January 2026), which lists the new psychoactive substances controlled at European Union level; control is a matter for national law. It is not listed in the schedules of the 1971 Convention on Psychotropic Substances (INCB Green List, 36th edition, 2025, text reviewed). No marketing authorisation was found.
- France
Not classified: GAT100 is not on the ANSM consolidated list of narcotics (updated 16/02/2026). This indole-2-carboxamide with an unsubstituted indole nitrogen falls within none of the generic families of that list, which target indoles substituted on the nitrogen, with a methanone, carboxylate or carboxamide bridge carried by carbon 3. No marketing authorisation was found.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
ECS pharmacological tool › Allosteric modulator
- Verification
Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.
- Wikipedia (English)
Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.
References
- Kulkarni PM et al. Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s). J Med Chem, 2016 (new tab)PMID 26529344
- Laprairie RB et al. Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe. ACS Chem Neurosci, 2016 (new tab)PMID 27046127
- PubChem, GAT100, CID 121453184 (identifiers and properties) (new tab)
Identifiers
Names
- IUPAC name
- 3-ethyl-5-isothiocyanato-N-[2-(4-piperidin-1-ylphenyl)ethyl]-1H-indole-2-carboxamide
- Other names
- GAT-100 · GAT 100
Identifiers
- Formula
- C₂₅H₂₈N₄OS
- CAS
- 1663564-42-8
- PubChem CID
- 121453184(new tab)
- InChIKey
- YIYLMDVRSNXYOT-UHFFFAOYSA-N
- SMILES
- CCC1=
C(NC2= C1C= C(C= C2) N= C= S) C(= O) NCCC3= CC= C(C= C3) N4CCCCC4
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.